Comparison of Heart Failure Medications Discovers Varied Risk of Death

In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death

In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years, according to a study in the January 12 issue of JAMA.

Angiotensin II receptor blockers reduce cardiovascular mortality and heart failure (HF) hospitalization in patients with HF with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction). Despite variable effects of different ARBs, they have not been tested head to head, and there are reasons to believe they may differ in efficacy, according to background information in the article. Previous research found that in elderly patients with HF, losartan was associated with higher mortality than other ARBs.

Poorly Educated At Greater Risk of Suffering From Heart Failure
Poorly educated people are more likely to be admitted to hospital with chronic heart failure than the better educated, even after differences in lifestyle have been taken into account,

Maria Eklind-Cervenka, M.D., of the Department of Cardiology, South Hospital, Stockholm, and colleagues conducted a study to determine whether candesartan is associated with less all-cause mortality than losartan in patients with HF. The study included analysis of data from an HF registry (the Swedish Heart Failure Registry) of 30,254 patients registered from 62 hospitals and 60 outpatient clinics between 2000 and 2009. A total of 5,139 patients (average age, 74; 39 percent women) were treated with candesartan (n = 2,639) or losartan (n = 2,500).

In overall survival between the 2 groups, the researchers found that one-year survival was 90 percent for patients receiving candesartan and 83 percent for patients receiving losartan, and 5-year survival was 61 percent for patients receiving candesartan and 44 percent for patients receiving losartan. The results persisted in stratified analyses.

The researchers add that there are mechanistic reasons to believe candesartan may be more effective than losartan and that studies of candesartan have been larger and more conclusively positive than studies of losartan.

Study Says Health Literacy Impacts Chance of Heart Failure Hospitalization
Being able to read and understand words like anemia, hormones and seizure means a patient with heart failure may be less likely to be hospitalized, says study

"In conclusion, our findings suggest that candesartan is associated with less all-cause mortality than losartan. However, clinical decision making should await supportive evidence of this observed association. Ideally, different ARB agents should be tested against each other in randomized controlled trials. It would also be important and perhaps more feasible to confirm our findings in other large HF registries," the authors write.

Heavy Smokers Carry an Elevated Risk of Heart Failure
A study from University of Alabama at Birmingham cautions heavy smokers about the constant risk of heart failure, even though some of them may have abstained from smoking for a decade or more.

Source-Eurekalert

Gene-silencing Aids in the Prevention of Diabetes-related Heart Failure
In a recent study it has been pointed that switching off TLR4 gene results in the prevention of cardiovascular disease in diabetic patients.